Immune Regulation by Extracellular Vesicles (EVs) {#S1}
=================================================

There are three main types of EVs formed by a cell, namely exosomes, microvesicles, and apoptotic bodies (ApoBDs). These three types of EVs vary in size, content, and mechanism of formation (Figure [1](#F1){ref-type="fig"}) ([@B1]). To date, exosomes and microvesicles generated from healthy cells are more extensively characterized and the formation of these EVs is key in mediating intercellular communication and immune regulation. Exosomes and microvesicles have been shown to play an important role in processes including antigen presentation, immune suppression, antitumor immunity, and autoimmunity. This has been the subject of many reviews, highlighting how EVs modulate immune responses by a myriad of mechanisms ([@B2]--[@B5]). Of particular interest is how the contents of exosomes and microvesicles enable them to regulate immune cell functions. Notably, these EVs can exhibit immune activating or immune suppressing properties depending on the specific circumstances. For example, exosomes have been shown to either activate or dampen the overall cytokine response through regulation of gene expression in monocytes and release of soluble cytokine receptors, respectively ([@B6], [@B7]). Exosomes derived from dendritic cells, B lymphocytes, and tumor cells have also been shown to regulate immunological memory through the surface expression of antigen-presenting MHC I and MHC II molecules, and subsequently eliciting T cell activation and maturation ([@B8]--[@B12]). Exosomes can also play a role in cross-presentation pathways and have been shown to promote dendritic cell activation and maturation ([@B12]). Furthermore, microvesicles can modulate immune responses by transporting cytokines such as IL-1β ([@B13]) and proinflammatory microRNAs ([@B14]).

![Extracellular vesicle (EV) formation and immune functions of apoptotic cell-derived EVs (ApoEVs). **(A)** Healthy cells form two main types of EV, namely exosomes that are release *via* exocytosis of multivesicular bodies, and microvesicles that are shed from the plasma membrane. During apoptosis, dying cells can also release ApoEVs. Apoptotic cells can undergo morphological changes including membrane blebbing, thin membrane protrusion formation (microtubule spikes, apoptopodia, and beaded-apoptopodia), and generation of distinct apoptotic bodies (ApoBDs). Apoptotic cells can also release EVs that are similar in size as microvesicles (ApoMVs), however, it is unclear if ApoMVs are generated *via* the same mechanism as microvesicles from healthy cells. Whether apoptotic cells can generate vesicles that are similar to exosomes is undetermined. **(B)** ApoEVs can harbor "find-me" signals (e.g., CX3CL1 and ICAM-3) to attract phagocytic cells, as well as "eat-me" signals \[e.g., ICAM-3, phosphatidylserine (PtdSer), and sialylated and glycosylated ligands\] to promote uptake by phagocytes. **(C)** ApoEVs have MHC II molecules on their surface, which is essential for direct antigen presentation to naïve CD4^+^ T cells and activation of immunological memory. ApoEVs can also carry antigen to professional antigen-presenting cells (e.g., dendritic cells). Antigens carried by ApoEVs include autoantigens, tumor antigens, and microbial antigens. **(D)** ApoEVs can promote inflammation by transporting proinflammatory cytokines such as IL-1α and damage-associated molecular patterns including DNA and HMGB1. **(E)** ApoEVs can aid HIV infection by inhibiting dendritic cell activation. Chikungunya virus (CHIKV) can hijack ApoEVs to propagate infection to neighboring cells.](fimmu-09-01486-g001){#F1}

Both exosomes and microvesicles are generally described as EVs released from healthy cells, however, dying cells can also release a variety of EVs, broadly known as apoptotic cell-derived EVs (ApoEVs) (Figure [1](#F1){ref-type="fig"}) ([@B1], [@B15], [@B16]). Subtypes of ApoEVs include large membrane-bound vesicles like ApoBDs ([@B15], [@B17]) or smaller apoptotic microvesicles (ApoMVs) ([@B18], [@B19]), both of which are described in detail below. While it has been well established that EVs can exhibit immunomodulatory effects, most studies have focused on EVs released from healthy cells, with EVs released from dying cells largely understudied. Nevertheless, a number of studies have suggested that ApoEVs have similar functional importance as EVs released from healthy cells. ApoEV formation has two key proposed functions: (a) aiding apoptotic cell clearance and (b) means of intercellular communication, both of which have implications in immune regulation. Many cells in the body are constantly undergoing apoptosis, and while a large portion of these are healthy cells undergoing normal turnover, apoptosis also occurs in many immunological and disease settings including inflammation, infection, autoimmunity, and cancer ([@B20]--[@B23]). Here, we discuss how ApoEVs may act as an immunomodulatory mechanism for apoptotic cells.

Generation of EVs During Apoptosis {#S2}
==================================

As first described by Kerr et al., during apoptosis a cell undergoes a series of morphological changes resulting in the dismantling of the dying cell ([@B17]). Recently, disassembly of the apoptotic cell is categorized into three distinct morphological steps, namely apoptotic membrane blebbing, thin membrane protrusion formation, and ultimately generation of ApoBDs that are generally defined as 1--5 µm in diameter ([@B15], [@B17]) (Figure [1](#F1){ref-type="fig"}). While less is known about the mechanisms driving the formation of ApoBDs compared to other types of EVs, recent studies suggest that it is a highly regulated process and has been reviewed in detail ([@B15], [@B16], [@B24]). Besides ApoBDs, cells can also release smaller EVs such as ApoMVs (\<1 μm in diameter) during the progression of apoptosis, possibly through membrane budding ([@B18], [@B19], [@B25], [@B26]). However, molecular regulators of ApoMVs formation are not well defined.

It is important to note that in the literature there are striking discrepancies in the characterization and isolation of ApoEVs ([@B27], [@B28]). Aside from size, currently there are no well-defined criteria to distinguish ApoBDs from other ApoEVs, in particular ApoMVs. Although proteomic studies comparing these ApoEV subtypes have been performed ([@B25], [@B26]), clear standard for the characterization and purification of ApoEV subtypes is lacking (highlighted in Table [1](#T1){ref-type="table"}). These discrepancies make it difficult to draw accurate conclusions regarding the functions of ApoEVs and caution should be taken when interpreting data involving ApoEVs. Taking these limitations into consideration, here we use the general term ApoEVs where it is unclear which subtype of ApoEVs is presented in a given study, and ApoBDs and ApoMVs to describe vesicles predominantly \>1--5 µm and \<1 μm in diameter, respectively.

###### 

Variation in nomenclature and isolation/characterization methods in articles describing the immunomodulatory properties of ApoEVs.

  Author and year                     Reference   Nomenclature used by the authors                            Summary of main findings                                                                                                                                                                                                                                                                                                                 Isolation/characterization method                                                                                                                                                                                                                                                                                                                                            ApoEV subtype (ApoBDs, ApoMVs, or unclear[^a^](#tfn1){ref-type="table-fn"})
  ----------------------------------- ----------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Segundo et al. (1999)               ([@B39])    Apoptotic blebs                                             Cell-depleted supernatant from apoptotic B cells stimulated macrophage chemotaxis. When the supernatant was passed through a 0.1 µm filter this effect was lost, suggesting larger vesicles are responsible for the observed effect                                                                                                      Centrifugation at 300 *g* to remove cells, followed by 100,000 *g* spin to collect vesicles. Purity of cell-depleted supernatant validated by microscopy                                                                                                                                                                                                                     Mix of ApoMVs and ApoBDs
  Thery et al. (2001)                 ([@B25])    ApoMVs                                                      Proteomics analysis of exosomes and apoptotic vesicles was performed and showed differential enrichment of proteins between each vesicle type. Total vesicle number increased in the apoptotic samples                                                                                                                                   Isolation of ApoEVs by differential centrifugation (300, 1,200, 10,000, and 110,000 *g*). Vesicles were further characterized by flow cytometry and exposure of surface PtdSer monitored                                                                                                                                                                                     Mix of ApoBDs and ApoMVs
  Schaible et al. (2003)              ([@B57])    Apoptotic vesicles                                          Apoptotic vesicles from tuberculosis-infected macrophages transferred bacterial antigen to dendritic cells. After engulfment of these apoptotic vesicles, dendritic cells could then crossprime CD8^+^ T cells                                                                                                                           Isolation of ApoEVs by differential centrifugation (800, 1,800, 25,000, and 100,000 *g*). Size of vesicles used not described                                                                                                                                                                                                                                                Unclear
  Distler et al. (2005)               ([@B43])    Microparticles                                              Engulfment of ApoEVs by macrophages induced macrophage apoptosis and the release of microparticles                                                                                                                                                                                                                                       Centrifugation at 1,500 *g* to remove cells, followed by 100,000 *g* spin to collect vesicles. Vesicles further characterized by flow cytometry                                                                                                                                                                                                                              Mix of ApoMVs and ApoBDs
  Winau et al. (2006)                 ([@B58])    Apoptotic vesicles                                          Vaccination with apoptotic vesicles protected mice against tuberculosis infection                                                                                                                                                                                                                                                        Isolation of ApoEVs by differential centrifugation (800, 1,800, 25,000, and 100,000 *g*). Size of vesicles validated by EM (approximately 500 nm)                                                                                                                                                                                                                            Unclear, likely ApoMVs
  Schiller et al. (2008)              ([@B53])    ApoBDs                                                      Autoantigens such as H2B and DNA, RNA were distributed into ApoBDs from lymphoblasts, which were subsequently engulfed by monocyte-derived phagocytes. Lymphoblasts showed an increase in vesicle formation during apoptosis                                                                                                             Centrifugation at 300 *g* to remove cells, and the supernatant passed through a 1.2 µm filter, followed by 100,000 *g* spin to collect vesicle. Large ApoBDs may be excluded. Vesicle size determined by EM (approximate 500 nm)                                                                                                                                             Mix of ApoMVs and some ApoBDs
  Truman et al. (2008)                ([@B37])    Apoptotic microparticles                                    CX3CL1/fractalkine released as vesicle-associated signal from apoptotic B lymphocytes                                                                                                                                                                                                                                                    Cell-free supernatant was used (procedure not described). Vesicles were further characterized by flow cytometry and exposure of surface PtdSer monitored                                                                                                                                                                                                                     Unclear
  Fransen et al. (2009)               ([@B36])    Apoptotic blebs                                             Apoptotic blebs were engulfed more efficiently than apoptotic cells by dendritic cells. Only the blebs but not the apoptotic cells induced dendritic cell maturation and IL-6 release                                                                                                                                                    Apoptotic cells were centrifuged at 1,550 *g* (this pellet is likely to contain large ApoBDs). Supernatant were centrifuged at 15,700 *g* to isolate "apoptotic blebs." No vesicle size validation described                                                                                                                                                                 Mix of ApoMVs and ApoBDs
  Reich and Pisetsky (2009)           ([@B52])    Microparticles                                              Microparticles contained DNA and RNA that antibodies could access                                                                                                                                                                                                                                                                        Centrifugation at 400 *g* to remove cells, and the supernatant passed through a 1.2 µm filter. Small ApoBDs may be included. No vesicle size validation described                                                                                                                                                                                                            Mix of ApoMVs and some ApoBDs
  Berda-Haddad et al. (2011)          ([@B42])    ApoBDs, microparticles                                      ApoBDs but not microparticles contained IL-1α and induced neutrophil infiltration *in vivo*                                                                                                                                                                                                                                              Centrifugation at 300 *g* to remove apoptotic cells, followed by 4,500 and 75,000 *g* spin to collect vesicles. Apoptotic supernatant was analyzed by flow cytometry, and different sized beads were used to identify 1--3 µm events (ApoBDs) and 0.5--1 µm events (microparticles)                                                                                          ApoBDs and ApoMVs
  Krejbich-Trotot et al. (2011)       ([@B71])    Apoptotic blebs                                             Infection of HeLa cells with Chikungunya virus induced apoptosis and infection of neighboring cells. Blocking blebbing and apoptotic bleb formation decreased infection of neighboring cells                                                                                                                                             Analyzed vesicle function using inhibitors of membrane blebbing (ROCK1 inhibitors and actin polymerization inhibitors). Vesicle size not determined                                                                                                                                                                                                                          ApoBDs, possibly ApoMVs
  Bilyy et al. (2012)                 ([@B50])    Subcellular membranous particle (scMP)                      Glycosylated ligands were detected on the surface of scMP, which acted as an "eat-me" signal for macrophages                                                                                                                                                                                                                             Procedure for isolating scMP and vesicle size validation not described. scMP population monitored by flow cytometry                                                                                                                                                                                                                                                          Unclear
  Farinacci et al. (2012)             ([@B56])    Apoptotic vesicles                                          Apoptotic vesicles from tuberculosis-infected macrophages activated dendritic cells following engulfment and subsequently primed CD4^+^ and CD8^+^ T cells                                                                                                                                                                               Isolation of ApoEVs by differential centrifugation (800, 1,800, 25,000, and 100,000 *g*). Vesicle size determined by EM (40--250 nm)                                                                                                                                                                                                                                         ApoMVs
  Frleta et al. (2012)                ([@B70])    Apoptotic microparticles                                    HIV infection induced the production of apoptotic microparticles that could suppress the ability of dendritic cells to prime CD8 T cells                                                                                                                                                                                                 Centrifugation at 400 *g* to remove cells, and the supernatant ultracentrifuged at 100,000 *g*. Vesicles were further characterized by flow cytometry and exposure of surface PtdSer monitored. Vesicle size determined by EM (0.1--1 µm)                                                                                                                                    ApoMVs and possibly some ApoBDs
  Schiller et al. (2012)              ([@B19])    Apoptotic cell-derived membrane microparticles (AdMPs)      Apoptotic microparticles stimulated dose-dependent IFN-α production from plasmacytoid dendritic cells, whereas supernatants from viable or necrotic cells had no effects                                                                                                                                                                 Centrifugation at 500 *g* to remove cells, and the supernatant passed through a 1.2 µm filter followed by 100,000 *g* spin to collect vesicles. Small ApoBDs may be included. Vesicles further characterized by flow cytometry                                                                                                                                               Mix of ApoMVs and some ApoBDs
  Torr et al. (2012)                  ([@B40])    Apoptotic microparticles                                    ICAM-3 was lost from the surface of apoptotic cells with the formation of ICAM-3-associated apoptotic microparticles. These vesicles promoted macrophage recruitment, while vesicles from ICAM-3 deficient cells were less effective                                                                                                     Centrifugation at 350 *g* to remove apoptotic cells, and the supernatant was used. Vesicle size determined by dynamic light scattering (average 200 nm in diameter, much smaller than expected based on the isolation procedure)                                                                                                                                             Mix of ApoMVs and ApoBDs
  Fehr et al. (2013)                  ([@B63])    Apoptotic cell-derived membrane vesicles, apoptotic blebs   Apoptotic blebs increased expression of dendritic cell activation markers, but decreased MHC II on dendritic cells. Apoptotic blebs-treated dendritic cells failed to induce T cell proliferation                                                                                                                                        Centrifugation at 500 *g* to remove cells, and the supernatant passed through a 1.2 µm filter. Small ApoBDs may be included. Vesicles further characterized by flow cytometry                                                                                                                                                                                                Mix of ApoMVs and some ApoBDs
  Schiller et al. (2013)              ([@B69])    Apoptotic cell-derived membraneous vesicles (ACMVs)         HMGB1 detected in vesicles generated during apoptosis                                                                                                                                                                                                                                                                                    Centrifugation at 500 *g* to remove cells, and the supernatant passed through a 1.2 µm filter followed by 100,000 *g* spin to collect vesicles. Small ApoBDs may be included. Vesicles further characterized by flow cytometry                                                                                                                                               Mix of ApoMVs and some ApoBDs
  Eguchi et al. (2015)                ([@B41])    Microparticles                                              Adipocyte microparticles promoted monocyte chemotaxis both *in vitro* and *in vivo*                                                                                                                                                                                                                                                      The supernatant following centrifugation at 2,000 *g* was used. Exposure of surface PtdSer on vesicles monitored by flow cytometry                                                                                                                                                                                                                                           Mix of ApoMVs and ApoBDs
  Niessen et al. (2015)               ([@B44])    AdMPs                                                       Uptake of apoptotic microparticles by macrophages promoted the release of proinflammatory cytokines IL-6, IL-8, and TNFα                                                                                                                                                                                                                 Centrifugation at 500 *g* to remove cells, and the supernatant passed through a 1.2 µm filter followed by 100,000 *g* spin. Small ApoBDs may be included. Size of vesicles used not described                                                                                                                                                                                Mix of ApoMVs and some ApoBDs
  Zirngibl et al. (2015)              ([@B54])    ACMVs                                                       Autoantigen histone H2B was shown to be loaded into apoptotic vesicles in a cytoskeleton-dependent manner                                                                                                                                                                                                                                Monitored apoptotic vesicles by microscopy and classified into small (\<1 μm), medium (1--3 µm), or large (\>3 μm) vesicles                                                                                                                                                                                                                                                  N/A
  Black et al. (2016)                 ([@B51])    Apoptotic vesicles                                          CD169 (macrophage adhesin molecule) on apoptotic vesicles suppressed dendritic cell-mediated cytotoxic T cell response                                                                                                                                                                                                                   Isolation of ApoEVs by differential centrifugation (25,000 *g* pellet). Sucrose gradient was used to separate ApoEVs from non-apoptotic material (only used fractions with β-actin). Vesicle size determined by CryoEM (35--814 nm)                                                                                                                                          ApoMVs
  Muhsin-Sharafaldine et al. (2016)   ([@B66])    Apoptotic vesicles, MVs                                     Apoptotic vesicles were able to activate naïve T cells and stimulate immunological memory *via* vesicle-associated MHC/antigen complex                                                                                                                                                                                                   Centrifugation at 450 and 3,200 *g* to remove cells, followed by a 25,000 *g* spin. Sucrose gradient was used to separate ApoEVs, microparticles, and exosomes. Vesicle size determined by CryoEM and dynamic light scattering (103--816 nm)                                                                                                                                 ApoMVs
  Sisirak et al. (2016)               ([@B64])    Apoptotic microparticles                                    DNA contained in apoptotic microparticles was shown to be antigenic when not digested by DNase1L3 and could contribute to an SLE-like condition                                                                                                                                                                                          Centrifugation at 1,500 rpm to remove cells, followed by 22,000 *g* spin to collect vesicles from apoptotic cells generated *in vitro*. Centrifugation at 2,000 *g* to remove cells, followed by 22,000 *g* spin to collect vesicles from plasma. Vesicles further characterized by flow cytometry and exposure of surface PtdSer monitored                                  Mix of ApoBDs and ApoMVs
  Ainola et al. (2017)                ([@B18])    ApoBDs, apoptotic particles, apoptotic microparticles       Noted an increase in vesicles formation (ApoBDs and microparticles) when HeLa cells were exposed to apoptotic stimuli. These vesicles mediated autoantigen transfer to plasmacytoid dendritic cells, resulting in proinflammatory cytokine production. Highlighted differences between subtypes of vesicles generated during apoptosis   Isolation of ApoEVs by differential centrifugation at 357 *g* (cell pellet), 1,400 *g* (ApoBDs), 16,000 *g* (ApoBDs and microvesicles), and 100,000 g (microvesicles). ApoEVs were further characterized by flow cytometry, ApoBDs (1--4 µm), and ApoMVs (0.1--1 µm), based on sizing beads. Authors commented on size overlap and how complete separation is not possible   ApoBDs, ApoMVs, mix of ApoBDs and ApoMVs
  Tucher et al. (2018)                ([@B26])    Apoptotic cell-released large EVs and small EVs             Noted an increase in large EVs (200--1,000 nm) being released from T cells following the induction of apoptosis. Performed proteomic analysis on different EV subsets and identified several proteins that may be specific to T cell ApoEVs                                                                                              Centrifugation at 300 *g* to remove cells, supernatant passed through a 1.2 µm filter. Further centrifugation at 10,000 *g* to pellet large EVs followed by 100,000 *g* to pellet small EVs. Vesicle size distribution determined by nanoparticle tracking analysis                                                                                                          Mix of ApoMVs and some ApoBDs

*^a^Where there was no indication from the purification procedure if the ApoEVs used were ApoMVs (50--1,000 nm) or ApoBDs (1,000--5,000 nm)*.

*ApoMVs, apoptotic microvesicles; ApoBDs, apoptotic bodies; ApoEVs, apoptotic cell-derived EVs; PtdSer, phosphatidylserine; EVs, extracellular vesicles; SLE, systemic lupus erythematous*.

ApoEVs Aid Removal of Dying Cells {#S3}
=================================

It has been well established that apoptotic cells coordinate a number of intercellular signals to aid in their detection and removal, and these signals are critical to ensure the immunologically silent characteristic of apoptosis ([@B22], [@B29]). Defective apoptotic cell clearance has been identified as a key contributing factor to autoimmune disease, whereby cells that are unable to be cleared efficiently eventually undergo secondary necrosis and release potentially damaging proinflammatory contents and autoantigens ([@B30]--[@B32]). There has been mounting evidence suggesting that the release of ApoEVs during apoptosis can promote clearance of apoptotic material, with the mechanism underpinning this process discussed below ([@B33]--[@B36]).

"Find-Me" Signals in Association With ApoEVs {#S3-1}
--------------------------------------------

For efficient apoptotic cell clearance, the recruitment of phagocytic cells toward the site of cell death is essential. To this end, apoptotic cells can release molecular factors known as "find-me" signals to attract phagocytes. Traditional "find-me" signals include the release soluble factors such as ATP, UTP, CX3CL1/fractalkine, and lysophosphatidylcholine ([@B21], [@B22], [@B37], [@B38]). However, there is also evidence of ApoEV-associated "find-me" signals being released from apoptotic cells.

While few studies elucidated the specific molecules involved in ApoEV-mediated recruitment of phagocytes, they have demonstrated ApoEVs to exhibit chemoattractive properties ([@B39]--[@B41]). Nevertheless, the "find-me" signal CX3CL1/fractalkine was found to be released from apoptotic B lymphocytes in association with ApoMVs ([@B37]) and the chemoattractive molecule ICAM-3 was associated with ApoEVs generated from apoptotic lymphoma cells ([@B40]). It is interesting to note that ApoEVs appear to have preferential recruitment of macrophages but not neutrophils ([@B41]). Such selective recruitment of different phagocytes by ApoEVs may be related to the subtype of ApoEVs being released by the apoptotic cell, in which one study comparing endothelial cell-derived ApoEVs of different size showed that only larger ApoEVs (1--3 µm in diameter, corresponding to ApoBDs) promoted neutrophil migration, whereas smaller EVs (\<1 μm, corresponding to ApoMVs) could not ([@B42]). It is worth noting that this phenomenon has been observed *in vitro* as well as *in vivo*, where intraperitoneal administration of ApoBDs in a mouse model stimulated neutrophil infiltration ([@B42]). Thus, different subtype of ApoEVs may have distinct functions in apoptotic cell clearance.

ApoEV Formation Promotes Engulfment {#S3-2}
-----------------------------------

Besides attracting phagocytes, formation of ApoEVs, in particular cell fragmentation into ApoBDs has been suggested to enhance removal of apoptotic material, an effect probably attributed to the size of ApoBDs being smaller bite-size pieces that can easily be engulfed by phagocytes. Supporting this concept, it has been shown that dendritic cells can more readily engulf smaller ApoBDs than whole apoptotic cells ([@B16], [@B36]). Furthermore, cells undergoing apoptotic cell disassembly and therefore producing ApoEVs are more efficiently engulfed by macrophages ([@B33], [@B43], [@B44]).

It should be noted that exposure of "eat-me" signals, such as phosphatidylserine (PtdSer), on apoptotic cells label them for clearance by phagocytes ([@B22], [@B45]). Likewise, ApoEVs can also expose "eat-me" signals like PtdSer on their surface and be recognized by macrophages for removal *via* phagocytic receptors such as CD36 ([@B43], [@B46]--[@B49]). Interestingly, ApoEVs can also expose ICAM-3, and specific sialylated and glycosylated ligands on its surface to trigger recognition and engulfment by macrophages ([@B40], [@B50], [@B51]).

ApoEVs As Key Regulators of Antigen Presentation {#S4}
================================================

An important immunomodulatory property of EVs is their ability to aid antigen presentation, a fundamental process for adaptive immunity. As mentioned above, EVs like exosomes have been shown to mediate antigen presentation *via* direct and cross-presentation mechanisms ([@B8]--[@B12]). Similarly, ApoEVs can also regulate antigen presentation *via* these mechanisms in a number of disease settings including autoimmunity ([@B18], [@B52]--[@B54]), antimicrobial immune responses ([@B55]--[@B58]), and organ/transplant rejection ([@B59]). Direct antigen presentation involves the vesicle carrying surface MHC molecules in complex with antigenic peptide to directly interact with naïve T cells ([@B60]). ApoEVs generated from dendritic cells and B16-F1 melanoma cells carried MHC II molecules suggesting the potential of ApoEVs to activate CD4^+^ T cells ([@B61]). Alternatively, cross-presentation relies on the vesicle transporting the antigen to professional antigen-presenting cells, in particular dendritic cells, for antigen processing and presentation to CD8^+^ T cells ([@B62]). In one study, ApoEVs generated from *Mycobacterium tuberculosis*-infected mouse macrophages were found to transfer bacterial-derived antigens to dendritic cells, and subsequently activate naïve CD8^+^ T cells ([@B57]). Furthermore, engulfment of ApoEVs by dendritic cells has also been shown to modulate their antigen-presenting capabilities. ApoEVs generated from lymphoblasts were found to suppress immune responses by downregulating MHC II molecules on dendritic cells ([@B63]).

While the mechanisms underpinning the ability of ApoEVs to modulate antigen presentation are diverse, it is clear that ApoEVs can contribute to the development of autoimmunity, and establishment of antitumor and antimicrobial immunity by regulating the antigen presentation process, as discussed further in detail below.

ApoEVs as Mediators of Autoimmunity {#S4-1}
-----------------------------------

As discussed above, impaired clearance of dying cells is a major factor contributing to the development of autoantibodies in autoimmune conditions ([@B30]--[@B32]). Although the formation of ApoEVs has been shown to promote apoptotic cell clearance ([@B36], [@B40], [@B43], [@B51]) and thus limiting the release on intracellular antigenic and proinflammatory contents, ApoEVs formation has also been proposed as a mechanism of facilitating the transport of autoantigens to antigen-presenting cells and drive autoimmunity. In particular, ApoEVs have been implicated in the development of systemic lupus erythematous (SLE), whereby autoantigens such as histone H2B can be translocated into ApoEVs during the early stages of apoptosis in HeLa cells *via* a microtubule driven mechanism ([@B54]). Lymphoblast-derived ApoEVs containing histone were also more readily engulfed by monocyte-derived phagocytes ([@B53]). Furthermore, ApoEV-associated autoantigens like DNA can bind directly to antinuclear antibodies ([@B52], [@B64]), a common feature of autoimmune conditions ([@B65]). In addition to autoantigens associated with SLE, Sjögren's syndrome nuclear autoantigens, such as hy1-RNA, are also detectable in both ApoMVs and ApoBDs generated from epithelial cells and can be transferred to dendritic cells *via* these ApoEVs ([@B18]).

Promoting Antitumor Immunity Through ApoEVs {#S4-2}
-------------------------------------------

With most cancer treatments focusing on inducing apoptosis in tumor cells, it becomes important to consider how the release of ApoEVs from dying tumor cells will impact the immune response toward the tumor. Recently, it has been shown that ApoMVs derived from tumorigenic apoptotic melanoma cells can promote antitumor immunity, in which mice immunized with ApoMVs generated from B16-F1 cells following doxorubicin treatment were protected against subsequent tumor challenges ([@B61]). Importantly, the tumor antigen PMEL was also found in ApoMVs ([@B66]), supporting the concept that ApoMVs can facilitate the transport of tumor antigens to antigen-presenting cells to promote antitumor immunity. It is interesting to note that despite ApoMVs having a relatively lower quantity of the tumor antigen PMEL as compared to other EVs like exosomes, the antitumor protective effect of ApoMV immunization was greater ([@B61]), suggesting that ApoMVs may aid antigen presentation *via* a different mechanism as other EVs and were able to promote a more robust antitumor immune response. As discussed earlier, "eat-me" signals such as PtdSer are present on ApoEVs ([@B43], [@B46]). Interestingly, another "eat-me" signal, calreticulin, that are exposed on certain apoptotic tumor cells can play a key role in promoting antitumor immunity through dendritic cells ([@B23], [@B48], [@B67], [@B68]). Therefore, it would be of interest to determine whether calreticulin is present on ApoEVs and whether exposure of calreticulin is important for ApoEV-mediated antitumor immunity.

Establishing Antimicrobial Immunity Through ApoEVs {#S4-3}
--------------------------------------------------

In addition to the presentation of self-antigens, it is important to note that under conditions where infected cells undergo apoptosis, the resultant ApoEVs may also harbor antigens from the infectious agent. The transfer of microbial-derived antigens *via* ApoEVs to antigen presentation cells like dendritic cells have been shown to provide a protective effect for the host. For example, ApoEVs released from apoptotic macrophages infected with the *M. tuberculosis* can be engulfed by peripheral monocyte-derived and splenic dendritic cells, which could subsequently activate the engulfing dendritic cells to prime naïve CD4^+^ or CD8^+^ T cells ([@B56]--[@B58]). Significantly, ApoEVs generated from *M. tuberculosis*-infected cells were able to be used to vaccinate naïve animals and provided protection against tuberculosis infection, highlighting the potential use of ApoEVs as vaccines ([@B58]). While these studies focus on tuberculosis infection, ApoEVs could play an important role in regulating antimicrobial immunity against other pathogens, however, these remain underexplored.

ApoEVs Modulate Immune Cell Responses {#S5}
=====================================

In addition to antigens, ApoEVs can harbor a variety of biomolecules that could directly modulate immune cells, most commonly *via* vesicle-associated cytokines or damage-associated molecular patterns (DAMPs), which could drive inflammation and dictate the immune cell responses. For example, proinflammatory cytokine IL-1α was detected in ApoBDs but not ApoMVs generated from endothelial cells induced to undergo apoptosis by prothrombic and hypoxic conditions *in vitro* ([@B42]). In a mouse model, administration of these endothelial cell-derived ApoBDs into the peritoneal cavity was able to induce production of neutrophil chemokines and promote neutrophil infiltration to drive sterile inflammation ([@B42]). Furthermore, an increase in IFN-α production by plasmacytoid dendritic cells in response to DNA in lymphoblast-derived ApoMVs was comparatively more pronounced than DNA isolated from whole cells ([@B19]). In this case, vesicle-associated DAMPs were responsible in promoting dendritic cell maturation, with the potential to promote damaging inflammation and possibly autoimmune conditions ([@B19], [@B53]). Besides DNA, other DAMPs such as HMGB1 can also be found in ApoEVs derived from peripheral blood mononuclear cells and T cells ([@B26], [@B69]).

Hijacking ApoEVs During Viral Infections {#S6}
========================================

The potential protective effects of ApoEVs in infection was discussed earlier, however, ApoEVs have also been implicated in facilitating the spread of infection *via* two different mechanisms. First, ApoEVs generated from infected cells could modulate the immune response and makes it favorable for the progression of infection. ApoMVs generated during HIV infection were able to modulate the dendritic cells response *via* binding to the CD44 receptor, resulting in decrease cytokine production from dendritic cells and inhibition of their ability to prime T cells or natural killer cells ([@B70]). Second, ApoEVs could directly aid viral propagation by mediating the transfer of infectious virions to neighboring cells. Chikungunya virus was shown to induce apoptosis and the formation of ApoBDs in infected HeLa cells and blocking ApoBD formation by targeting the apoptotic cell disassembly process pharmacologically limited infection spreading to neighboring cells ([@B71]). Thus, although the formation of ApoEVs by infected cells could be beneficial for the host by facilitating the antigen presentation process, certain viruses may hijack ApoEVs to aid viral propagation.

Conclusion {#S7}
==========

Overall, there is compelling evidence to support the importance of ApoEVs in immune modulation, and ApoEVs can play a significant role across many aspects of immunity and disease settings. Therefore, ApoEVs are more than just debris or by-products of apoptosis and should be considered as a key mechanism for apoptotic cells to communicate with surrounding cells. The ability of ApoEVs to either activate or dampen immune responses demonstrates the fine balance between the beneficial effects of ApoEV generation and the potentially damaging implications. However, as highlighted in this review, there are marked discrepancies in the characterization and isolation of ApoEVs, making it difficult to accurately define their functions. To progress the field, it is critical to identify suitable criteria to distinguish different subtypes of ApoEVs and develop better experimental systems to modulate ApoEV formation under physiologically relevant conditions.
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